NAD+ (1000 mg Vial) Dosage Protocol

Supplies Needed

Supply estimates follow the calculation schedule above and assume one new syringe plus two alcohol swabs per day.

• Peptide Vials (NAD+, 1000 mg each):
  • 8 weeks: 6 vials (approximately 5,075 mg calculated)
  • 12 weeks: 8 vials (approximately 7,875 mg calculated)
  • 16 weeks: 11 vials (approximately 10,675 mg calculated)
• Insulin Syringes (U-100, 1 mL):
  • 8 weeks: 56 syringes
  • 12 weeks: 84 syringes
  • 16 weeks: 112 syringes
• Bacteriostatic Water (10 mL bottles):
  • 8 weeks: 18 mL → 2 bottles
  • 12 weeks: 24 mL → 3 bottles
  • 16 weeks: 33 mL → 4 bottles
• Alcohol Swabs:
  • 8 weeks: 112 swabs - 2 boxes required (100 swabs each)
  • 12 weeks: 168 swabs - 2 boxes required (100 swabs each)
  • 16 weeks: 224 swabs - 3 boxes required (100 swabs each)

Sharps safety: Place used needles and syringes in an FDA-cleared sharps container immediately after use; never reuse them.

View Supplier

View Supplier

View Supplier

View Supplier

NAD+ 1000 mg Protocol Overview

The purpose of this 1000 mg protocol page is to make the preparation math explicit. Adding 3.0 mL of diluent produces 333.33 mg/mL. On a U-100 syringe, each unit represents 0.01 mL, so each unit contains about 3.33 mg of NAD+. The same arithmetic applies throughout the chart: milligrams divided by 333.33 mg/mL equals injection volume, and milliliters multiplied by 100 equals U-100 units.

• 50 mg: 50 ÷ 333.33 = 0.15 mL = 15 units.
• 75 mg: 75 ÷ 333.33 = 0.225 mL = 22.5 units.
• 100 mg: 100 ÷ 333.33 = 0.30 mL = 30 units.

This page does not treat container size as evidence for a dose. A 1000 mg format changes the number of administrations available and the supply totals; it does not establish a different biological dose range than another strength. Readers comparing the NAD+ 500 mg vial protocol should therefore focus on concentration and syringe-volume differences rather than assuming the larger format requires a larger amount per administration.

What Is NAD+ and What Does It Do?

NAD+ is the oxidized form of nicotinamide adenine dinucleotide. It accepts electrons in cellular redox reactions and cycles with NADH, its reduced form. This NAD+/NADH pair participates in glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation, and other pathways that support cellular energy production.^[1][5]

NAD+ is also consumed by enzymes such as sirtuins, poly(ADP-ribose) polymerases, and CD38. Those pathways connect NAD metabolism with DNA-damage responses, cell signaling, stress adaptation, and inflammatory biology. Reviews consistently describe these mechanisms, but they also caution that promising mechanistic or animal findings do not automatically demonstrate a clinical benefit in humans.^[6][7]

Searches for “NAD injection dosage” often combine evidence about direct NAD+ administration with research on oral supplements containing precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These are related but not interchangeable interventions. A dose used for an oral precursor cannot be converted into an injected NAD+ dose by simple milligram comparison.

Human NAD+ Research and Evidence Limits

Direct human evidence for administered NAD+ is sparse. A pharmacokinetic pilot study infused 750 mg of NAD+ intravenously over six hours in healthy men and measured changes in plasma and urinary metabolites. The study helps describe what happened during a supervised IV infusion, but it did not test the daily amounts in this chart and was not designed to establish an anti-aging, energy, or disease-treatment dose.^[3]

An observational report described NAD+ combined with enkephalinase-inhibiting therapy in people with substance-use disorders. Its design, combined intervention, and clinical setting limit what can be concluded about NAD+ alone.^[2] A systematic review of NAD+ and NADH studies likewise found heterogeneous formulations, routes, populations, and outcomes; it did not identify a validated general-purpose injection schedule.^[4]

More recent reviews emphasize that much of the human literature involves NAD+ precursors rather than injected NAD+ itself. A 2025 review characterized human efficacy evidence as limited and tissue-specific, while a 2026 systematic review reported no eligible outcomes trials of intravenous or intramuscular NAD+ itself for anti-aging or wellness indications.^[7][8] That distinction is why the primary chart on this page is labeled community-reported use rather than a clinical protocol.

How to Read an NAD+ Injection Guide

Search phrases such as NAD dosage, injection dosage, dosage per day, mg per injection, mg per dose, and times per week describe different parts of a protocol. A dosage chart can convert a selected amount into milliliters and syringe markings, but that calculation does not establish which dose, frequency, or route is clinically appropriate. This page therefore separates arithmetic from evidence instead of presenting the community table as a validated dosage guide.

Routes are not interchangeable. IV therapy is an infusion setting performed under medical supervision, while the subcutaneous route places a smaller volume beneath the skin. The published 750 mg per session study does not validate 750 mg of NAD+ by another route, high-dose NAD+ outside that setting, or a general schedule of three times per week, daily injections, or other injection protocols.^[3][4] Controlled human evidence has not established a universal per-injection amount or frequency.

The same limit applies to shorthand searches for SubQ injections, subcutaneous protocols, 2-3 times per week, three injections per week, or mg per day. Those phrases cannot substitute for controlled data, and subcutaneous or intramuscular routes should not be treated as equivalent. Published evidence does not establish general dosage ranges or subcutaneous doses; “750 mg IV” refers to a specific supervised infusion study. Questions about NAD+ and injection dosing should separate the dose of NAD+ arithmetic from evidence for a schedule. Storage guidelines and container size affect handling and calculations, not the biological dose.

NAD+ Injection Route: IV Evidence vs Route Calculations

Route changes the context. Intravenous administration places a solution directly into the bloodstream under clinical supervision. Administration beneath the skin places a smaller volume into subcutaneous tissue, where absorption occurs over time. The published 750 mg study used a six-hour IV infusion; it therefore cannot validate the absorption, tolerability, or outcome of a 0.15–0.30 mL administration by another route.^[3]

The primary table is best read as a reconstitution and syringe-conversion tool. It answers how a selected amount maps to volume after the 1000 mg product is prepared with 3.0 mL. It does not answer what dose a person should use. The absence of controlled subcutaneous NAD+ dosing trials is a central evidence limitation, not a gap that can be filled by extrapolating from IV infusions or oral NR/NMN studies.^[6][8]

NAD+ 1000 mg Reconstitution and Measurement Calculations

Three equations control the entire NAD+ dosage chart:

1. Concentration: compound mass ÷ final volume = mg/mL.
2. Injection volume: selected mass ÷ concentration = mL.
3. U-100 markings: mL × 100 = syringe units.

For this preparation, 1000 mg ÷ 3.0 mL = 333.33 mg/mL. A 25 mg calculation would equal 0.075 mL, or 7.5 U-100 units. A 125 mg calculation would equal 0.375 mL, or 37.5 units. These examples demonstrate arithmetic only and are not additional schedule recommendations. Higher doses should never be inferred from container size or syringe capacity.

Decimal accuracy matters. Rounding 333.33 mg/mL to 333 mg/mL has little effect at the amounts shown, but rounding volume too early can change the syringe marking. Calculate with the full concentration first, then round the final U-100 result to a marking that the selected syringe can actually display. U-100 units describe liquid volume; they do not indicate the biological potency of NAD+.

NAD+ Storage and Handling

Use the exact product label, lot documentation, and validated stability instructions as the controlling source. The supplier identifies the 1000 mg product and its batch documentation; that product information is not evidence for a clinical dose.^[12]

• Before preparation: keep the sealed product dry, protected from light, and within the manufacturer’s labeled temperature range.
• After preparation: label the container with the concentration and date, refrigerate at 2–8°C (36–46°F), and protect it from light.
• Inspection: do not use a solution that is cloudy, discolored, contains visible particles, or has been stored outside verified conditions.
• Use-by period: do not infer a universal discard date from container strength alone. Follow product- and preparation-specific stability information.

NAD+ Injection Side Effects and Safety Context

General injection-technique resources describe using a new sterile needle and syringe, cleaning the preparation area, rotating sites, and disposing of sharps immediately after use.^[9][10] These general resources do not endorse NAD+ injections or the schedule on this page.

• Confirm the syringe is U-100 before using the unit conversions shown here.
• Use a new sterile syringe for every administration and never share injection equipment.
• Rotate the injection site rather than repeatedly using the same point.
• Keep volume per injection separate from compound mass: 0.30 mL is a volume, while 100 mg is the calculated NAD+ mass at this concentration.
• Recognize that injection discomfort can be affected by volume, formulation, speed, site, and technique.^[11]

NAD+ 1000 mg Frequently Asked Questions

How much bacteriostatic water is used for a 1000 mg NAD+ preparation?

This page uses 3.0 mL as its calculation volume, producing 333.33 mg/mL. A different final volume would require every mL and U-100 conversion to be recalculated.

How many U-100 units equal 50 mg at 333.33 mg/mL?

Fifty milligrams equals 0.15 mL, which is 15 units on a U-100 syringe.

How many U-100 units equal 100 mg?

One hundred milligrams equals 0.30 mL, or 30 U-100 units, at the concentration used on this page.

Is there an established NAD+ injection schedule per day?

No general daily NAD+ dose has been established by controlled human trials. Published parenteral evidence is limited and primarily concerns supervised intravenous use, so the table should be treated as community-reported calculation context rather than a clinical recommendation.^[4][8]

Does a 1000 mg strength require a larger dose than a 500 mg strength?

No. Container size changes total available mass and may change concentration after reconstitution. It does not independently determine an appropriate amount per administration.

Are NR and NMN doses interchangeable with injected NAD+?

No. NR and NMN are NAD+ precursors with different absorption and metabolism. Human precursor trials cannot be converted directly into an injected NAD+ schedule.^[6][7]

Are oral NAD+, compounded NAD+, and NAD IV therapy interchangeable?

No. These labels describe different formulations and routes, with different concentration, absorption, handling, and evidence questions. Results or amounts from one format should not be transferred to another without route-specific evidence.